LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a 36-month stability study of the cells from its Master Cell Bank (MCB). These cells will be encapsulated and then used
Read more →LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial results for its second quarter ended October 31, 2021, and provided an overview of recent operational highlights (PharmaCyte’s Fiscal Year begins May 1 and ends
Read more →LAGUNA HILLS, CA, December 8, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of an additional, more detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the
Read more →LAS VEGAS, November 30, 2021–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the commencement of a pivotal study to determine if the treatment PharmaCyte uses for locally
Read more →LAS VEGAS, NV, November 12, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that makes up its CypCaps™ pancreatic cancer product does not cause skin irritation. PharmaCyte’s Chief
Read more →LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test of biocompatibility of its CypCaps™ product candidate for pancreatic cancer. The tests results showed that the empty capsule material is
Read more →LAGUNA HILLS, CA, September 21, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of a second U.S. Food and Drug Administration (FDA)-required test of biocompatibility of its CypCaps product for pancreatic
Read more →LAGUNA HILLS, CA, September 16, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the first test results of the biocompatibility studies of its CypCaps™ clinical trial product candidate. These results were from an
Read more →LAGUNA HILLS, CA, September 8, 2021 (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held
Read more →LAGUNA HILLS, CA, August 31, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing
Read more →